Cyfuse Biomedical KK

Cyfuse Biomedical KK FCF Margin

The Free Cash Flow Margin of Cyfuse Biomedical KK (4892.T) as of Nov 2, 2026 is -251.92 %. In the previous year, Free Cash Flow Margin was -1,410.87 % — a change of -82.14% (higher).

FCF Margin

-251.92 %

YoY

-82.14%

Last updated:

Free Cash Flow Margin of Cyfuse Biomedical KK is 2025 -251.92 % . Free Cash Flow Margin of Cyfuse Biomedical KK was 2024 -1,410.87 % . It decreases by -82.14% higher compared to the previous year.

The Cyfuse Biomedical KK FCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Margin
Date
FCF Margin
Jan 1, 2020
-214.04 JPY
Jan 1, 2021
22.81 JPY
Jan 1, 2022
-168.73 JPY
Jan 1, 2023
-951.97 JPY
Jan 1, 2024
-1,410.87 JPY
Jan 1, 2025
-251.92 JPY
The Cyfuse Biomedical KK FCF Margin history
YEARFCF MarginYoY
-251.92 %-82.14%
-1,410.87 %+48.21%
-951.97 %+464.18%
-168.73 %-839.80%
22.81 %-110.66%
-214.04 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cyfuse Biomedical KK Stock analysis

What does Cyfuse Biomedical KK do? Cyfuse Biomedical KK develops and manufactures cell regenerative systems, focusing on regenerative medicine products and drug discovery support tools. The company sells three-dimensional cell stacking system equipment, which includes basic technology and apply technology for cell product development. Its primary customers are pharmaceutical companies seeking drug discovery support and institutions requiring regenerative medicine solutions. The firm generates revenue through the sale of equipment and contract research services for cell products in the regenerative medicine field. Cyfuse Biomedical KK's business model centers on developing and selling three-dimensional cell stacking systems, which are used as tools for drug discovery support. The company also provides contract research services for cell products, targeting pharmaceutical companies and research institutions. Revenue streams include equipment sales and contract research, with a focus on regenerative medicine applications and drug discovery support. The company's product portfolio includes three-dimensional cell stacking system equipment, which incorporates basic technology and apply technology for cell product development. These systems are sold to pharmaceutical companies and research institutions for use in regenerative medicine and drug discovery. The firm's revenue is derived from the sale of equipment and the provision of contract research services in the regenerative medicine sector. Cyfuse Biomedical KK is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cyfuse Biomedical KK stock

Free Cash Flow Margin of Cyfuse Biomedical KK is -251.92 % in 2025.

Free Cash Flow Margin of Cyfuse Biomedical KK changed from -1,410.87 % to -251.92 %, representing a -82.14% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Margin Cyfuse Biomedical KK since 2006 – with annual values, charts, and detailed analysis.

FCF Margin measures the percentage of revenue converted to free cash flow. It indicates how efficiently a company generates cash from its operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Margin's Cyfuse Biomedical KK with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Cyfuse Biomedical KK

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Cyfuse Biomedical KK